Last updated: 11/07/2018 01:09:09
A multi-national, multi-centre, randomized, double-blind, parallel-group study to determine the effects of carvedilol on mortality and morbidity in patients with left ventricular dysfunction, with or without clinical evidence of heart failure, post myocardial infarction.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A multi-national, multi-centre, randomized, double-blind, parallel-group study to determine the effects of carvedilol on mortality and morbidity in patients with left ventricular dysfunction, with or without clinical evidence of heart failure, post myocardial infarction.
Trial description: A multi-national, multi-centre, randomized, double-blind, parallel-group study to determine the effects of carvedilol on mortality and morbidity in patients with left ventricular dysfunction, with or without clinical evidence of heart failure, post myocardial infarction.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Capricorn: a story of alpha allocation and beta-blockers in left ventricular dysfunction post-mi. Coats, A. J. Int J Cardiol 2001; 78(2):109-13
Landmark study: The carvedilol post-infarct survival control in left ventricular dysfunction study (capricorn). Colucci, W. S. Am J Cardiol 2004; 93(9A):13B-6B
New evidence from the capricorn trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Sackner-Bernstein, J. D. Rev Cardiovasc Med 2003; 4 Suppl 3(S25-9)
The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet 2001; 357: 1385-1390.
Medical condition
Left Ventricular Dysfunction
Product
carvedilol
Collaborators
Not applicable
Study date(s)
June 1997 to Invalid Date
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website